Actuate Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-03-28. It has amended it 3 times. It filed its final prospectus on 2024-08-13, at a public offering price of $8.00 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our Common Stock is currently listed on The Nasdaq Global Market (“Nasdaq”) under the symbol “ACTU.” On July 24, 2025, the last reported sales price of our Common Stock, as reported on Nasdaq, was $6.99 per share.From the S-1 filed 2025-07-25
Shares offered
This is the initial public offering of shares of common stock of Actuate Therapeutics, Inc. We are offering 2,800,000 shares of our common stock.From the 424B4 filed 2024-08-13
Offering price
The initial public offering price per share of common stock is $8.00.From the 424B4 filed 2024-08-13
Use of proceeds
We intend to use the net proceeds from this offering, along with our existing cash and cash equivalents, for clinical trials and product development, research and development, clinical manufacturing as well as for working capital and other general corporate purposes.From the 424B4 filed 2024-08-13
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-07-16 | Registration statement amended | S-1/A |
| 2024-07-19 | Registration statement amended | S-1/A |
| 2024-07-23 | Registration statement amended | S-1/A |
| 2024-08-13 | Final prospectus filed: the offering is priced | 424B4 |
| 2025-03-28 | Registration statement filed | S-1 |
| 2025-07-25 | Registration statement filed | S-1 |
Tools for this story
Each opens in a new tab, filled in for Actuate Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.